FDA Endorses Proteinuria Reduction Endpoint in Dimerix’s Pivotal Kidney Trial

• FDA confirms proteinuria reduction at 2 years as primary endpoint for DMX-200 approval
• Blinded statistical powering analysis delayed to early 2026 pending additional FDA documentation
• ACTION3 trial targets focal segmental glomerulosclerosis (FSGS), a rare kidney disease
• DMX-200 holds orphan drug designation and patent protection through 2032, with extensions possible